glp-1 and dual glp-1/gip receptor agonists Major physiological roles of GIP. Tirzepatide is acting as an GLP‑1 Receptor Agonists and Preclinical

Because studies have evaluated GHK-Cu across multiple cell types (including fibroblasts and keratinocytes) and in preclinical models, it is commonly used to support mechanistic work on aging-related tissue changes, repair biology, and copper homeostasisstrictly within controlled research designs

These potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent

Research-use note GHK-Cu referenced here is intended strictly for in-vitro laboratory and educational research

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial